Clarivate : Q1 2024 – Supplemental Materials

Q1 2024

Earnings Call

May 8, 2024

1. Introduction

Mark Donohue VP Investor Relations

Safe Harbor Statement and Non-GAAP Financial Measures

Forward-Looking Statements

This communication includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "intends," "plans," "may," "will," or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts, and include statements regarding our intentions, beliefs, or current expectations concerning, among other things, anticipated cost savings, results of operations, financial condition, liquidity, prospects, growth, strategies, and the markets in which we operate. Such forward-looking statements are based on available current market material and management's expectations, beliefs and forecasts concerning future events impacting us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors of our annual report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.

Non-GAAP Financial Measures

This presentation contains financial measures which have not been calculated in accordance with United States generally accepted accounting principles ("GAAP"), including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, and Free Cash Flow because they are a basis upon which our management assesses our performance, and we believe they reflect the underlying trends and indicators of our business. Although we believe these measures may be useful for investors for the same reasons, these financial measures should not be considered as an alternative to GAAP financial measures as a measure of the Company's financial condition, profitability, performance and liquidity. In addition, these financial measures may not be comparable to similar measures used by other companies. In the Appendix to this presentation, we provide further descriptions of these non-GAAP measures and reconciliations of these non-GAAP measures to the corresponding most closely-related GAAP measures.

Industry and Market Data

The market data and other statistical information used throughout this presentation are based on industry publications and surveys, public filings, and various government sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. We have not independently verified such third-party information, nor have we ascertained the underlying economic assumptions relied upon in those sources, and we are unable to assure you of the accuracy or completeness of such information contained in this annual report. While we are not aware of any misstatements regarding our market, industry, or similar data presented herein, such data involve risks and uncertainties and are subject to change based on various factors.

3

Agenda

1. Introduction	Mark Donohue
	Vice President
	Investor Relations

2. Business Review	Jonathan Gear
	Chief Executive Officer

3. Financial Review	Jonathan Collins
	Executive Vice President and
	Chief Financial Officer

4. Q&A

All

4

2. Business Review

Jonathan Gear Chief Executive Officer

Q1 2024 highlights

	Revenues
$621M	1.7% organic decline
	2.4% organic subscription growth

Presented Clarivate segment updates and AI strategy, a key enabler to drive future growth

Leveraging best-in-class content and technology to drive innovation in A&G

$236M

Adj. EBITDA¹

38% margin1

Delivering actionable intelligence, integrated solutions and services in IP

$112M

Free Cash Flow1

Driving growth in LS&H through scalable platforms and AI-driven workflow solutions

47% Conversion

14₵

Adj. EPS1

Progressed key initiatives across IP Patent Intelligence and LS&H Real

World Data

(4)₵ YoY

1See the Appendix for a reconciliation of GAAP to Non-GAAP measures.

6

Leveraging best-in-class content and technology to drive innovation in Academia & Government

Realizing Our Growth Opportunity

Research & Analytics

Content Aggregation

Workflow Solutions

Drive actionable research insights across more domains through new Research Intelligence solution

Expand the premier content marketplace and aggregation portfolio internationally (non-English)

Reach into more customer tiers, extend geographies, and expand decision analytics

Alethea (Academic Coach)

AI Strategy

Advance Existing Solutions

Web of Science Research Assistant ProQuest Research Assistant

Innovate With New Solutions

Alethea (Academic Coach)

Web of Science Research Assistant

7

Delivering actionable intelligence and integrated solutions and services in Intellectual Property

Realizing Our Growth Opportunity

Patent and Trademark Intelligence

Patent and Trademark Management

Patent and Trademark Maintenance Solutions

Deliver use-case-specific intelligence embedded in decision-making processes to help customers gain competitive advantage

Create a connected ecosystem of data, workflow solutions and expertise to drive productivity and collaboration in IP mgmt.

Leverage our domain knowledge and tech- enabled services to become an integral extension of our customers' teams

IP Forecast

AI Strategy

Advance Existing Solutions

IP Forecast

Portfolio Benchmarking & AI Classifier

Innovate With New Solutions

Patent Intelligence Watching

Portfolio Benchmarking & AI Classifier

8

Driving growth through scalable platforms and AI driven workflow solutions in Life Sciences & Healthcare

Realizing Our Growth Opportunity

Corporate

Research and Development

Commercial

Embed our market intelligence into workflows, translating data into recommended actions

Consolidate into scalable core platforms and leverage AI to drive product quality and advanced analytics

Build enriched pharma-grade subscription- based real world data solutions focusing on differentiated therapy areas and indications

Cortellis Q&A Conversational Search

AI Strategy

Advance Existing Solutions

Innovate With New Solutions

Cortellis	Q&A Conversational Search
Cortellis	Contextual Insights

AI-driven Competitive Intelligence through MotionHall Acquisition

Cortellis Contextual Insights

9

Progressed key initiatives across IP Patent Intelligence and LS&H Real World Data

Intellectual Property | Patent Intelligence

Life Sciences & Healthcare | Real World Data

Released Streamlined Patent Search Capability

Launched Derwent Innovation Search Management beta to market

Increased Customer Renewal Rates

Derwent Q1 renewal rate increased by ~2% compared to same period last year

Released New Real World Data Framework

Driving higher level of quality and insights through comprehensively mastered medical claims data

Achieved Commercial Milestone

Secured first deal underpinned by our new real- world-data framework with a top 10 global pharmaceutical customer¹

Progressed Next Gen AI Powered Releases

On track for release of Derwent Innovation AI Search and AI Watch Solutions

Increased Data Coverage

Expanded our portfolio of data assets with integration of new data sets across Latin America and Germany

1Top 20 Pharma Companies by 2023 Revenue (FiercePharma).

10